An exception to this includes the IDO inhibitor, 1-methyltryptophan, which was shown to enhance chemotherapeutic effects in both the murine orthotopic 4T1 and the autochthonous MMTV-neu breast cancer models (70). This evidence concerns the gene ERBB2 and breast cancer.